SEC Filing Document

Company: Synergy CHC Corp.
Ticker: SNYR
CIK: 1562733
Filing Type: S-1/A
Document Type: EX-1.1
Date Filed: 2024-07-29
Accession Number: 0001013762-24-002165
Exchange: Nasdaq
SIC Code: 2833
SIC Description: Medicinal Chemicals & Botanical Products
URL: https://www.sec.gov/Archives/edgar/data/1562733/000101376224002165/ea020832402ex1-1_synergy.htm

Chunk 2 of 15
Word Count: 1264
Character Count: 7978

Document Content:

upon and all times after the effectiveness of such requirements. Absence of Manipulation. The Company has not taken, directly or indirectly, any action that is designed to or that has constituted or that would reasonably be expected to cause or result in the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of the Shares. (xii) Investment Company Act. The Company is not and, after giving effect to the offering and sale of the Shares and the application of the net proceeds thereof, will not be an “investment company,” as such term is defined in the Investment Company Act of 1940, as amended. Representations and Warranties Regarding the Company. The Company represents and warrants to, and agrees with, the several Underwriters, as of the date hereof and as of the Closing Date and as of each Option Closing Date, as follows:

Good Standing. Each of the Company and its subsidiaries has been duly organized and is validly existing as a corporation or other
entity in good standing under the laws of its jurisdiction of incorporation. Each of the Company and its subsidiaries has the power and
authority (corporate or otherwise) to own its properties and conduct its business as currently being carried on and as described in the
Registration Statement, the Time of Sale Disclosure Package and the Prospectus, and is duly qualified to do business as a foreign corporation
or other entity in good standing in each jurisdiction in which it owns or leases real property or in which the conduct of its business
makes such qualification necessary, except where the failure to so qualify would not have or be reasonably likely to result in a material
adverse effect upon the business, prospects, properties, operations, condition (financial or otherwise) or results of operations of the
Company and its subsidiaries, taken as a whole, or in its ability to perform its obligations under this Agreement (“Material
Adverse Effect”).

Authorization. The Company has the power and authority to enter into this Agreement and
the Underwriter Warrants and to authorize, issue and sell the Shares and the Underwriter
Warrant Shares as contemplated by this and the Underwriter Warrants. This Agreement and
the Underwriter Warrants have been duly authorized by the Company, and when executed and delivered by the Company, and will constitute
the valid, legal and binding obligations of the Company, enforceable against the Company in accordance with their respective terms, except
as rights to indemnity hereunder may be limited by federal or state securities laws and except as such enforceability may be limited
by bankruptcy, insolvency, reorganization or similar laws affecting the rights of creditors generally and subject to general principles
of equity.

(iii)
Contracts. The execution, delivery and performance of this Agreement and the Underwriter
Warrants and the consummation of the transactions herein contemplated will not (A) result in a breach or violation of any of the
terms and provisions of, or constitute a default under, any law, order, rule or regulation to which the Company or any subsidiary is
subject, or by which any property or asset of the Company or any subsidiary is bound or affected, (B) conflict with, result in any violation
or breach of, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, or give to
others any right of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) (a “Default
Acceleration Event”) of, any agreement, lease, credit facility, debt, note, bond, mortgage, indenture or other instrument (the
“Contracts”) or obligation or other understanding to which the Company or any subsidiary is a party or by which any
property or asset of the Company or any subsidiary is bound or affected, except to the extent that such conflict, default, or Default
Acceleration Event not reasonably likely to result in a Material Adverse Effect, or (C) result in a breach or violation of any of the
terms and provisions of, or constitute a default under, the Company’s Certificate of Incorporation or by-laws.

No Violations of Governing Documents. Neither the Company nor any of its subsidiaries is in violation, breach or default under
its certificate of incorporation, by-laws or other equivalent organizational or governing documents.

Consents. No consents, approvals, orders, authorizations or filings are required on the part of the Company in connection with
the execution, delivery or performance of this Agreement and the Underwriter Warrants and the issue and sale of the Securities, except
(A) the registration under the Securities Act of the Securities, which has been effected, (B) the necessary filings and approvals from
the Nasdaq to list the Securities, (C) such consents, approvals, authorizations, registrations or qualifications as may be required under
state or foreign securities or Blue Sky laws and the rules of the Financial Industry Regulatory Authority, Inc. (“FINRA”)
in connection with the purchase and distribution of the Shares by the several Underwriters, (D) such consents and approvals as have been
obtained and are in full force and effect, and (E) such consents, approvals, orders, authorizations and filings the failure of which
to make or obtain is not reasonably likely to result in a Material Adverse Effect.

Capitalization. The Company has an authorized capitalization as set forth in the Registration Statement, the Time of Sale Disclosure
Package and the Final Prospectus. All of the issued and outstanding shares of capital stock of the Company are duly authorized and validly
issued, fully paid and nonassessable, and have been issued in compliance with all applicable securities laws, and conform in all material
respects to the description thereof in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus. All
of the issued shares of capital stock of each subsidiary of the Company have been duly and validly authorized and issued, are fully paid
and non-assessable and, except as set forth in the Registration Statement, the Time of Sale Disclosure Package and the Final Prospectus,
are owned directly or indirectly by the Company, free and clear of all liens, encumbrances, equities or claims. Except for the issuances
of options or restricted stock in the ordinary course of business, since the respective dates as of which information is provided in
the Registration Statement, the Time of Sale Disclosure Package or the Final Prospectus, the Company has not entered into or granted
any convertible or exchangeable securities, options, warrants, agreements, contracts or other rights in existence to purchase or acquire
from the Company any shares of the capital stock of the Company. The Shares, when issued and paid for as provided herein, will be duly
authorized and validly issued, fully paid and nonassessable, will be issued in compliance with all applicable securities laws, and will
be free of preemptive, registration or similar rights and will conform to the description of the capital stock of the Company contained
in the Registration Statement, the Time of Sale Disclosure Package and the Prospectus. The shares
of Common Stock issuable upon the exercise of the Underwriter Warrants (the “Underwriter Warrant Shares”), when issued,
paid for and delivered upon due exercise of the Underwriter Warrants, as applicable, will be duly authorized and validly issued, fully
paid and nonassessable, will be issued in compliance with all applicable securities laws, and will be free of preemptive, registration
or similar rights. The Underwriter Warrant Shares have been reserved for issuance. The Underwriter Warrants, when issued, will conform
in all material respects to the descriptions thereof set forth in the Registration Statement, the Time of Sale Disclosure Package and
the Final Prospectus.